Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines

Evolus Inc EOLS presented interim data from its Phase 2 clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau (prabotulinumtoxinA-xvfs), its flagship neurotoxin product, at the 2023 International Master Course on Aging Science World Congress.
The data indicated that the "extra-strength" formulation of Jeuveau at 40U (units) achieved a duration profile of 6 months or 26 weeks.
The extra-strength glabellar (frown) line study is a multicenter, double-blind, randomized Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction.
The study had three arms: Jeuveau Extra-Strength 40U and two active controls, Botox 20U and Jeuveau 20U.
Jeuveau Extra-Strength demonstrated six months (26 weeks) duration, including the time it takes for patients to return to their baseline Glabellar Line Scale (GLS) score, time back to baseline for patients with a response of none or mild on the GLS, and the duration of effect of at least a one-point GLS improvement.
The adverse events profile across all three arms was similar. The severity rating demonstrated that 88% of the events were mild and 12% were moderate. No serious adverse events were reported.
Jeuveau is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65.
Price Action: EOLS shares closed at $10.25 on Friday.